PT3956322T - Inibidor seletivo de cinase jak1 - Google Patents

Inibidor seletivo de cinase jak1

Info

Publication number
PT3956322T
PT3956322T PT207906397T PT20790639T PT3956322T PT 3956322 T PT3956322 T PT 3956322T PT 207906397 T PT207906397 T PT 207906397T PT 20790639 T PT20790639 T PT 20790639T PT 3956322 T PT3956322 T PT 3956322T
Authority
PT
Portugal
Prior art keywords
kinase inhibitor
selective kinase
jak1 selective
jak1
inhibitor
Prior art date
Application number
PT207906397T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Dizal Jiangsu Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dizal Jiangsu Pharmaceutical Co Ltd filed Critical Dizal Jiangsu Pharmaceutical Co Ltd
Publication of PT3956322T publication Critical patent/PT3956322T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT207906397T 2019-04-19 2020-04-17 Inibidor seletivo de cinase jak1 PT3956322T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2019083376 2019-04-19

Publications (1)

Publication Number Publication Date
PT3956322T true PT3956322T (pt) 2025-06-04

Family

ID=72837031

Family Applications (1)

Application Number Title Priority Date Filing Date
PT207906397T PT3956322T (pt) 2019-04-19 2020-04-17 Inibidor seletivo de cinase jak1

Country Status (15)

Country Link
US (1) US12606544B2 (https=)
EP (1) EP3956322B1 (https=)
JP (1) JP7555959B2 (https=)
KR (1) KR20220003537A (https=)
CN (1) CN113710664B (https=)
AR (1) AR118729A1 (https=)
AU (1) AU2020258619C1 (https=)
BR (1) BR112021020964A2 (https=)
CA (1) CA3134174A1 (https=)
DK (1) DK3956322T3 (https=)
ES (1) ES3031576T3 (https=)
MX (1) MX2021012749A (https=)
PT (1) PT3956322T (https=)
TW (1) TWI910107B (https=)
WO (1) WO2020211839A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022111499A1 (zh) * 2020-11-26 2022-06-02 深圳铂立健医药有限公司 一种酰胺化合物、药物组合物及其应用
CN114380806B (zh) * 2022-03-24 2022-06-10 中国药科大学 2-氨基-4-吲哚基嘧啶类化合物及其制备方法与应用
US12240836B2 (en) * 2022-07-05 2025-03-04 Dong-A St Co., Ltd. Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof
EP4554931A1 (en) * 2022-07-12 2025-05-21 Adama Makhteshim Ltd. Process for preparing substituted benzamides
CN115260128B (zh) * 2022-09-21 2022-12-09 苏州凯瑞医药科技有限公司 一种新型jak抑制剂关键中间体的制备方法
GB202403369D0 (en) 2024-03-08 2024-04-24 Astrazeneca Ab Process and intermediates for the production of a jak1 inhibitor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9198900B2 (en) * 2011-11-10 2015-12-01 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Treatment of peritoneal injury using JAK inhibitors
JP6767491B2 (ja) 2015-09-25 2020-10-14 ディザル(ジァンスー)ファーマシューティカル・カンパニー・リミテッド Jakを阻害するための化合物及び方法
ES2938648T3 (es) * 2017-01-17 2023-04-13 Astrazeneca Ab Inhibidores selectivos de JAK1
CA3113732C (en) * 2018-09-21 2023-07-11 Shanghai Ennovabio Pharmaceuticals Co., Ltd. Aromatic heterocyclic compound with kinase inhibitory activity

Also Published As

Publication number Publication date
JP2022529061A (ja) 2022-06-16
JP7555959B2 (ja) 2024-09-25
EP3956322A4 (en) 2023-05-03
US20220220096A1 (en) 2022-07-14
EP3956322A1 (en) 2022-02-23
ES3031576T3 (en) 2025-07-09
AU2020258619A1 (en) 2021-09-16
MX2021012749A (es) 2021-11-18
CA3134174A1 (en) 2020-10-22
WO2020211839A1 (en) 2020-10-22
CN113710664A (zh) 2021-11-26
CN113710664B (zh) 2024-01-26
KR20220003537A (ko) 2022-01-10
AU2020258619C1 (en) 2026-01-29
AU2020258619B2 (en) 2025-10-23
TWI910107B (zh) 2026-01-01
US12606544B2 (en) 2026-04-21
DK3956322T3 (da) 2025-06-16
TW202104215A (zh) 2021-02-01
AR118729A1 (es) 2021-10-27
EP3956322B1 (en) 2025-05-14
BR112021020964A2 (pt) 2021-12-14

Similar Documents

Publication Publication Date Title
HUE071067T2 (hu) PARP1 inhibitorok
ZA201906875B (en) Jak1 selective inhibitors
IL276269A (en) Aminopyrrolotriazines as kinase inhibitors
PT3956322T (pt) Inibidor seletivo de cinase jak1
PT3305788T (pt) Inibidor da janus cinase
IL286363A (en) Benzodiazepine derivatives as rsv inhibitors
SI3704118T1 (sl) Aminoimidazopiridazini kot kinazni inhibitorji
GB201914860D0 (en) Inhibitor compounds
EP3783000A4 (en) MACROCYCLIC KINASE INHIBITOR
GB2603386B (en) Selective dihydropyrrolopyrimidine JAK2 inhibitors
GB201819126D0 (en) Inhibitor compounds
IL290087A (en) inhibitory substances
IL269144A (en) Pyrrolotriazine derivatives as kinase inhibitors
GB201905328D0 (en) Inhibitor compounds
IL281599A (en) TYK2 kinase inhibitors
PT4036095T (pt) Derivados de 4-fluoro-1h-pirazolo[3,4-c]piridina como inibidores seletivos de tirosina cinase de bruton (btk) para o tratamento de linfoma de células b e doenças autoimunes
GB201819136D0 (en) Inhibitor compounds
IL282941B1 (en) Rock kinase inhibitors
GB201807845D0 (en) Kinase Inhibitors
HK40069065A (zh) Jak1选择性激酶抑制剂
GB201914388D0 (en) Kinase inhibitors
GB201908044D0 (en) Dopamine-B-Hydroxylase inhibitors
GB201905476D0 (en) MAPA4K4 Inhibitors
GB201905318D0 (en) Inhibitor compounds
GB201806130D0 (en) Inhibitor compounds